(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...
Faron Pharmaceuticals has collaborated with cancer research organisation City of Hope to develop a Phase II investigator-initiated trial for evaluating bexmarilimab in participants with relapsed or ...
Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results